Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 1
2011 1
2012 1
2016 1
2020 2
2021 6
2022 5
2023 4
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

19 results

Results by year

Filters applied: . Clear all
Page 1
Effectiveness and safety of anti-IL-5/Rα biologics in eosinophilic granulomatosis with polyangiitis: a two-year multicenter observational study.
Nolasco S, Portacci A, Campisi R, Buonamico E, Pelaia C, Benfante A, Triggiani M, Spadaro G, Caiaffa MF, Scioscia G, Detoraki A, Valenti G, Papia F, Tomasello A, Crimi N, Scichilone N, Pelaia G, Carpagnano GE, Crimi C. Nolasco S, et al. Among authors: valenti g. Front Immunol. 2023 Jun 30;14:1204444. doi: 10.3389/fimmu.2023.1204444. eCollection 2023. Front Immunol. 2023. PMID: 37457743 Free PMC article.
Real-world characteristics of "super-responders" to mepolizumab and benralizumab in severe eosinophilic asthma and eosinophilic granulomatosis with polyangiitis.
Portacci A, Campisi R, Buonamico E, Nolasco S, Pelaia C, Crimi N, Benfante A, Triggiani M, Spadaro G, Caiaffa MF, Scioscia G, Detoraki A, Valenti G, Papia F, Tomasello A, Scichilone N, Pelaia G, Crimi C, Carpagnano GE. Portacci A, et al. Among authors: valenti g. ERJ Open Res. 2023 Oct 30;9(5):00419-2023. doi: 10.1183/23120541.00419-2023. eCollection 2023 Sep. ERJ Open Res. 2023. PMID: 37908397 Free PMC article.
Real-life effects of dupilumab in patients with severe type 2 asthma, according to atopic trait and presence of chronic rhinosinusitis with nasal polyps.
Pelaia C, Benfante A, Busceti MT, Caiaffa MF, Campisi R, Carpagnano GE, Crimi N, D'Amato M, Foschino Barbaro MP, Maglio A, Minenna E, Nolasco S, Paglino G, Papia F, Pelaia G, Portacci A, Ricciardi L, Scichilone N, Scioscia G, Triggiani M, Valenti G, Vatrella A, Crimi C. Pelaia C, et al. Among authors: valenti g. Front Immunol. 2023 Mar 30;14:1121237. doi: 10.3389/fimmu.2023.1121237. eCollection 2023. Front Immunol. 2023. PMID: 37063895 Free PMC article.
Omalizumab for the treatment of chronic spontaneous urticaria in clinical practice.
Bongiorno MR, Crimi N, Corrao S, Allotta A, Arena A, Brusca I, Heffler E, Malara G, Milioto M, Pistone G, Porto M, Raia E, Valenti G. Bongiorno MR, et al. Among authors: valenti g. Ann Allergy Asthma Immunol. 2016 Dec;117(6):703-707. doi: 10.1016/j.anai.2016.08.006. Epub 2016 Oct 6. Ann Allergy Asthma Immunol. 2016. PMID: 27720581 Review. No abstract available.
Indacaterol/glycopyrronium/mometasone fixed dose combination for uncontrolled asthma.
Pelaia C, Crimi C, Crimi N, Ricciardi L, Scichilone N, Valenti G, Bonavita O, Andaloro S, Morini P, Rizzi A, Pelaia G. Pelaia C, et al. Among authors: valenti g. Expert Rev Respir Med. 2022 Feb;16(2):183-195. doi: 10.1080/17476348.2021.2011222. Epub 2021 Dec 23. Expert Rev Respir Med. 2022. PMID: 34845963
Features of severe asthma response to anti-IL5/IL5r therapies: identikit of clinical remission.
Carpagnano GE, Portacci A, Nolasco S, Detoraki A, Vatrella A, Calabrese C, Pelaia C, Montagnolo F, Scioscia G, Valenti G, D'Amato M, Caiaffa MF, Triggiani M, Scichilone N, Crimi C. Carpagnano GE, et al. Among authors: valenti g. Front Immunol. 2024 Jan 23;15:1343362. doi: 10.3389/fimmu.2024.1343362. eCollection 2024. Front Immunol. 2024. PMID: 38327518 Free PMC article.
Adherence to omalizumab: A multicenter "real-world" study.
Campisi R, Crimi C, Intravaia R, Strano S, Noto A, Foschino MP, Valenti G, Viviano V, Pelaia C, Ricciardi L, Scichilone N, Crimi N. Campisi R, et al. Among authors: valenti g. World Allergy Organ J. 2020 Feb 12;13(2):100103. doi: 10.1016/j.waojou.2020.100103. eCollection 2020 Feb. World Allergy Organ J. 2020. PMID: 32082464 Free PMC article.
Patients and doctors group meetings: an innovative way to explore severe asthma backstage.
Caminati M, Camiciottoli G, Baiardini I, Antonicelli L, Beghè B, Crimi N, Favero E, Stanziola AA, Valenti G, Visca D, Del Giacco S. Caminati M, et al. Among authors: valenti g. Multidiscip Respir Med. 2022 Sep 5;17:854. doi: 10.4081/mrm.2022.854. eCollection 2022 Jan 12. Multidiscip Respir Med. 2022. PMID: 36158780 Free PMC article.
Effectiveness of benralizumab in severe eosinophilic asthma: Distinct sub-phenotypes of response identified by cluster analysis.
Di Bona D, Crimi C, D'Uggento AM, Benfante A, Caiaffa MF, Calabrese C, Campisi R, Carpagnano GE, Ciotta D, D'Amato M, Pelaia C, Pelaia G, Pellegrino S, Scichilone N, Scioscia G, Ribecco N, Spadaro G, Valenti G, Vatrella A, Crimi N, Macchia L. Di Bona D, et al. Among authors: valenti g. Clin Exp Allergy. 2022 Feb;52(2):312-323. doi: 10.1111/cea.14026. Epub 2021 Oct 16. Clin Exp Allergy. 2022. PMID: 34608696 Free PMC article.
19 results